Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...

Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

U.S. equities were mixed at midday, with the Nasdaq losing more than 1% on worries about future Federal Reserve interest-rate cuts.

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna lowers its full-year sales guidance by up to $1.0 billion. Moderna stock is now down close to 30% versus its YTD high ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...